Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.52 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350245 | 0.85 | HTR6 (0.55) | HTR6DRD2L3MBTL1CA12CA2 | |
| SCHEMBL5355112 | 0.83 | HTR6 (0.60) | HTR6DRD2L3MBTL1CA12CA2 | |
| SCHEMBL5350532 | 0.77 | HTR6 (0.51) | HTR6DRD2L3MBTL1CA12CA2 | |
| SCHEMBL5356793 | 0.74 | HTR6 (0.61) | HTR6DRD2L3MBTL1CA12CA2 | |
| SCHEMBL5358790 | 0.71 | HTR6 (0.65) | HTR6DRD2L3MBTL1CA12CA2 | |
| SCHEMBL3644542 | 0.70 | HTR6 (1.00) | HTR6DRD2L3MBTL1CA12CA2 | |
| SCHEMBL27757843 | 0.70 | HTR6 (0.59) | HTR6DRD2L3MBTL1CA12CA2 | |
| SCHEMBL7497262 | 0.70 | L3MBTL1 (0.60) | HTR6DRD2L3MBTL1CA12CA2 | |
| SCHEMBL1651879 | 0.69 | HTR6 (0.74) | HTR6DRD2L3MBTL1CA12CA2 | |
| SCHEMBL27622283 | 0.68 | HTR6 (0.69) | HTR6DRD2L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176230-B2 | Synthesis of indole analogs of 1-benzyl-3-(5′-hydroxymethyl-2′-furyl) indazole (YC-1) as anti-platelet agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2007-02-13 | — | — | US | disclosed |
| US-20060106041-A1 | Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106041-A1 | Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethy 1-2' -furyl) indazole (YC-1) as anti-platelet agents | PFKP, HMOX1, TPH1 | HTR6 85/4885DRD2 3084/4885L3MBTL1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.